The tumor suppressor gene MEN1 is frequently mutated in sporadic pancreatic 
Introduction
Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant syndrome, characterized by multiple tumors in endocrine tissues such as the pituitary gland, parathyroid gland and pancreatic islets (1). Linkage studies and positional cloning identified the causative gene, MEN1, for this disorder. Over 1300 mutations, typically truncating, have been identified in MEN1 (2, 3) . The importance of MEN1 inactivation in tumorigenesis is highlighted by the frequency of MEN1 mutations in sporadic endocrine tumors-44% in pancreatic neuroendocrine tumors and 35% in parathyroid adenomas (4, 5) . Heterozygous and conditional Men1 knockout mice develop tumors in multiple neuroendocrine tissues, recapitulating the spectrum of tumors in MEN-1 syndrome, with Men1 conditional knockout animals demonstrating a shorter latency (6) (7) (8) (9) . Although Men1 mutations are primarily associated with neuroendocrine cancers, several lines of evidence demonstrate that Men1 can also be mutated in non-neuroendocrine tumors such as lung cancer, melanoma and liver cancer (10) (11) (12) .
Several studies have implicated that menin, the protein product of MEN1, is involved in transcriptional regulation, cell cycle control, protein degradation and genome instability through interaction with a number of transcription factors such as JunD, NF-B and members of the Smad family (3, (13) (14) (15) . In addition, we and others have shown that menin is physically associated with Trithorax-like complexes containing the histone methyltransferases MLL1 (KMT2A) and MLL4 (KMT2B, previously MLL2), to promote trimethylation of histone H3 at lysine 4 (H3K4me3) (16, 17) . Surprisingly, menin also binds to the MLL fusion protein in leukemia cells to upregulate HoxA9 gene expression, thus promoting oncogenic activity in MLL-associated leukemiogenesis (18) .
Genome-wide analysis by chromatin immunoprecipitation coupled with DNA microarray analysis (ChIP-chip) (19) has revealed that menin colocalizes with MLL at gene promoters in various cell types, suggesting that menin regulates transcription in cooperation with MLL in multiple tissues (20) .
Currently there are no targeted therapies directed toward patients harboring pancreatic neuroendocrine cancer tumors with MEN1 mutations. Thus there is a critical need to deepen our understanding of the biology of these cancers to develop more effective therapeutic approaches. Given the inactivation of menin in multiple endocrine cancers and the reversibility of histone H3K4me3, we were interested in the role of enzymes that potentially antagonize the histone methylation activity of menin. Rbp2 (Kdm5a, Jarid1a), initially identified as Retinoblastoma-binding protein 2, is a member of the Jumonji (JMJ) domain-containing family of histone demethylases, with roles in chromatin modification and transcriptional regulation (21) . Loss of Rbp2 recruitment to the CDKN1B gene is highly correlated with increased histone H3K4me3 levels and elevated gene expression (21) (22) (23) . We have previously demonstrated in murine models that inactivation of the histone demethylase Rbp2 significantly inhibits tumor growth in Men1-deficent mice (24) . We also demonstrated that alterations in gene expression patterns upon Men1 loss in pancreatic islets are partially reversed by Rbp2 loss in these cells (24) . Collectively, these observations support the notion that (a) histone methylation plays a key role in Men1 deletion-mediated tumorigenesis in neuroendocrine cells, and (b) the demethylase enzyme activity of Rbp2 antagonizes the histone methyltransferase activity associated with menin at gene loci such as CDKN1B. Although loss of function of menin is known to play an important role in tumor initiation and progression in endocrine tissues (7), there is limited information on the mechanisms linking menin-HMT complexes to neuroendocrine-specific hyperplasia and tumorigenesis.
Men1-deficient mice can take up to a year to accumulate the numerous genetic and epigenetic alterations that result in tumor formation, a slow process during which pancreatic islet cells transform from normal to a hyperplastic and finally a malignant state (7) . Thus, this period represents a window of opportunity to investigate early events leading to tumorigenesis and to address the role of menin-HMT complexes in modulating cell proliferation and behavior at this pre-cancerous stage.
To investigate tumor formation mediated by alterations in H3K4me3 levels and to identify gene targets of menin-HMT complexes, we conducted epigenetic profiling of Men1-deficent pancreatic islets in 2 month-old Men1 conditional knockout mice and control wild-type littermates, Using chromatin immunoprecipitation techniques coupled with next-generation sequencing (ChIP-seq), we found that Men1 loss lowered H3K4me3 levels at select target gene promoters, resulting in downregulation of gene expression.
Additionally, loss of H3K4me3 correlated with increased H3K27me3 levels, consistent with the known association of H3K27me3 with gene repression (25) . Our study is the first to identify gene targets of menin-HMT complexes in mouse pancreatic islets in vivo along with the time course of the epigenetic changes accompanying mouse pancreatic neuroendocrine tumor formation.
Materials and methods

Mouse Experiments
Creation and genotyping of RIP-Cre mice, Men1 KO mice and Men1 Rbp2 double KO mice has been described previously (24) . Mice were maintained on a mixed 129s6, FVB/N, and C57BL/6 background. All procedures were carried out in in accordance with the National Research Council Guide for the Care and Use of laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Dana-Farber Cancer Institute.
Isolation of mouse pancreatic islets
Pancreatic islets were isolated as previously described (24) .
Histological and Immunohistochemical analysis for pancreatic tissues
Pancreata were collected from mice at indicated time points and fixed in 4% paraformaldehyde for 2 hours followed by dehydration and paraffin embedding.
Histopathological analysis was carried out on five-micrometer sections stained with hematoxylin and eosin. Islet morphology and tumors were examined in at least three cut sections for each pancreas after staining with hematoxylin and eosin. Appropriate positive and negative controls were run on matched sections for all applied antibodies.
Immunohistochemical staining was performed on serial sections using antibodies against were counterstained in Meyer's hemotoxylin, mounted and photographed using an Olympus microscope.
ChIP-seq
For each ChIP experiment, islets from at least 4 adult mice were purified by collagenase digestion and gradient centrifugation, with subsequent hand picking. ChIP was performed as described (26) using 4 g of anti-H3K4me3 (Active Motif, catalog no. 36159) or antiH3K27me3 antibodies (Cell Signaling Technology, catalog no. 9733). 5 to 50 ng of DNA was used for library construction. DNA was prepared for sequencing by Illumina cluster generation using a SPRI-work system with 100-300 bp size selection followed by enrichment with barcoded PCR primers for multiplexing. Sequencing was performed on a Hiseq2000 machine for 40 nucleotides from a single end, at the MIT BioMicro Center.
Barcode-separated FASTQ files were generated from QSEQ files.
ChIP-Seq data analysis
Forty nucleotides of sequenced reads were aligned to the mouse reference genome (mm9 assembly), using Bowtie aligner (27) . Only those reads/tags that mapped to unique genomic locations with at most two mismatches were retained for further analysis.
Histone mark peaks were detected using MACS (version 1.4.2) as previously described (28) 
Data availability
All ChIP-Seq data generated in this study have been deposited in the NCBI GEO repository (accession number GSE63020).
RNA isolation and RT-qPCR
Total RNA was isolated using the RNeasy kit (Qiagen) from 100 to 300 mouse pancreatic islets purified from 2 mice with different genotypes. RNA quality was assessed on the Table S5 .
Results
Inactivation of Men1 does not alter global H3K4me3 levels in pancreatic beta cells.
To address whether Men1 loss causes global changes in histone H3K4 methylation, we assessed H3K4me3 levels in Men1-deficient mouse pancreatic islets and control RIP-Cre islets by immunohistochemistry (IHC). We detected no significant change in the overall levels of H3K4me3 in Men1-deficient islets compared to wild-type islets (Fig. 1A ). Our finding is consistent with earlier studies demonstrating that in contrast to Set1a and Set1b, the major H3K4 trimethylases in mammalian cells (30) histone modifications for only a subset of genes in mouse pancreatic islets.
Menin-dependent H3K4me3 is altered during early stages of pancreatic neuroendocrine tumor formation.
To investigate locus-specific H3K4 trimethylation potentially regulated by meninHMTs in pancreatic islets, we performed ChIP-seq to identify genome-wide H3K4me3 occupancy in islets from 2 month-old RIP-Cre (control) mice or Men1-deficient mice.
We identified >22,000 H3K4me3 peaks, using the MACS algorithm (28) . As expected, H3K4me3 marks were most frequently observed at proximal promoter regions, near transcriptional start sites (TSSs)(16) ( 
Integrative analysis of H3K4 trimethylation and gene expression identifies menin-
HMT gene targets.
To determine whether the regulation of differentially expressed genes in Men1-deficient islets is dependent on menin-mediated H3K4me3, we integrated gene expression data (24) with H3K4me3 profile data. Genes whose expression was downregulated at least two-fold in Men1-deficient islets showed a significant reduction in H3K4me3 levels ( Fig. 2A) . In contrast, H3K4me3 levels were unchanged at genes upregulated at least two-fold upon menin loss (Fig. 2B) . Notably the H3K4me3 signal in downregulated loci was also generally lower than for genes showing increased expression upon Men1 loss (compare profiles of Figs. 2A, B) . These data suggest a direct role for menin-dependent H3K4me3 in activating gene expression from its target promoters in mouse pancreatic islets. The role of H3K4me3 in menin-dependent repression of gene expression however remains to be elucidated.
To identify genes that were downregulated and associated with reduced H3K4me3 levels in Men1-deficient islets we intersected these two datasets, revealing that 50 out of 365 genes showing reduced gene expression (14% overlap rate vs 1.7% expected random overlap rate; p-value<0.001) also exhibited lower H3K4me3 levels (Fig. 2C) . Many of these targets are linked to type 2 diabetes and beta cell functions (also see Fig. S1 ). These data indicate that gene repression mediated by menin under wild-type conditions likely occurs by mechanisms other than via reduction of H3K4 tri-methylation.
Men1-loss does not change histone modifications at known menin gene targets in mouse pancreatic islets, at age of 2 months.
A number of genes including Cdkn1b, Cdkn2c, Mnx1, Hoxa9, and Hoxc6, have been previously shown to be regulated by menin or menin-HMT complexes (16, 18, 20, 33, 34) . We, however, did not observe a significant difference in enrichment of H3K4me3 or reduction of H3K27me3 at the Cdkn1b, Cdkn2c, and Mnx1 promoters in Fig. S2 ), despite Cdkn1b and Cdkn2c being highly expressed in mouse pancreatic islets (WL, unpublished observations). These findings, although consistent with our prior observations (24) where we reported no significant difference in expression of these genes upon Men1 loss, are at odds with other studies using mouse embryonic fibroblasts (MEFs) and pancreatic islets that have demonstrated the role of trimethylation of H3K4 in transcriptional activation of Cdkn1b and Cdkn2c (34) . It is possible that expression of Cdkn1b and Cdkn2c does not require menin-HMT complexes at this stage.
Men1-deficient islets (Supplementary
Menin is also known to regulate the majority of Hox genes in MEFs (31) . Hox genes are typically bivalently modified in embryonic stem cells (32); however we did not observe strong H3K4me3 signals at these loci in pancreatic islets ( Supplementary Fig.   S3 ) although we detected strong H3K27me3 association with four Hox gene clusters Supplementary Fig. S3 ). Since H3K27me3 is associated with repression of gene expression, our results are consistent with microarray data showing that most Hox genes were silenced or expressed at very low levels (data not shown). Thus, at the time point being evaluated, menin-driven gene expression appears to occur via both H3K4me3-dependent and -independent mechanisms.
Loci with increased H3K27me3 signals in Men1-deficient islets are associated with decreased H3K4me3.
Trimethylation of histone H3K4 is mediated by trithorax group proteins including MLL1 and MLL4 and can antagonize H3K27 trimethylation mediated by polycomb group complexes such as PRC2 (35, 36) . To investigate this potential inverse correlation, we evaluated H3K27me3 levels by IHC in control, Men1 single knockout and Men1/Rbp2 double knockout islets. As observed for H3K4me3, we did not detect significant differences in overall expression of H3K27me3 (Fig. 3A) . We next asked whether loss of H3K4me3 in genes regulated by menin-HMT complexes altered H3K27me3 levels. We compared H3K27me3 signals on H3K4me3-marked regions classified as unchanged or decreased by Men1 loss (Figs. 1B gray and green points and 3B) (Fig. 3B) . We detected enrichment of H3K27me3 at promoters that showed decreased levels of H3K4me3 in Men1-deficient islets, but not at promoters with unaltered H3K4me3 occupancy (compare red tracings in Figs 3C & 3D) . In total, 37 out of 50 genes with both decreased expression and decreased H3K4me3 in Men1-deficient islets showed enhanced H3K27me3 (Supplementary Fig. S4 ). 
Dynamic time-dependent changes in H3K4me3 and H3K27me3 at the Igf2bp2
promoter.
Next, we sought to establish how H3K4me3 and H3K27me3 signals change over time during pancreatic islet tumorigenesis. We focused on the Igf2bp2 locus since Igf2bp2 was one of the two most down-regulated genes in Men1-deficient islets compared to RIP-Cre islets based on analysis of microarray data, and because the Igf2bp2 promoter showed the most dramatic change in H3K4me3 signal, of the 50 genes identified in our integrative analysis. We isolated pancreatic islets from control and Men1 knockout mice at 2, 6 and 12 months of age and tumors from Men1-deficient mice at 12 months. ChIP-seq to assess changes in H3K4me3 and H3K27me3 signals over time ( (Fig. 4B) . Many other genes also show a similar inverse relationship between H3K4me3 and H3K27me3 signals that was consistent during the progression of pancreatic islet tumorigenesis; examples include Gata6 and Oxtr (Supplementary Fig.   S5 ).
Igf2bp2 expression is epigenetically regulated during pancreatic islet tumor formation.
Analysis of our previously published microarray data demonstrated that Igf2bp2 expression is downregulated in Men1-deficent pancreatic islets and is partially restored in
Men1;Rbp2 double knockout islets (Fig. 5A) . We verified these observations by qPCR analysis, confirming that Igf2bp2 expression was decreased by 60% upon Men1 ablation and rescued to near-baseline levels in the Men1 Rbp2 double knockout condition (Fig.   5B ). ChIP-PCR revealed that H3K4me3 levels at the Igfbp2 locus in Men1-deficient islets decreased to <60% of control (consistent with the ChIP-seq data) and was restored to baseline in Men1 Rbp2 double knockout islets, whereas H3K4me3 signals in control regions (p53 and Gapdh) were unaltered (Fig. 5C) . In order to correlate the changes in Igf2bp2 mRNA expression with protein levels, we evaluated Igf2bp2 expression by IHC in pancreatic islets. We detected a marked reduction in Igf2bp2 protein in Men1-deficient islets compared to control RIP-Cre (Fig. 5D) . Consistent with transcript levels, Igf2bp2 protein levels were restored in Men1/Rbp2 double knockout islets. Collectively, these data reveal that Igf2bp2 is epigenetically regulated by menin-HMT complexes in mouse other mechanisms or may be independent of menin. Menin has also been reported to play a critical role during embryogenesis and MLL1-mediated leukemogenesis via regulation of Hox gene expression (31) .
Although several previous studies have focused on chromatin and gene expression targets of menin (20, 37) , we have identified different targets in our study. Previous studies utilized different experimental systems, either non-hyperplastic islets (20) as opposed to the hyperplastic islets in our study, or Men1-deficient mESCs and mouse pancreatic islet-like endocrine cells (PILECs) (37) . Furthermore, in studies of mouse embryos, we previously identified HoxC6 and HoxC8 as menin targets (16), but did not find these genes as targets in the current study, suggesting the possibility that Hox genes might be the targets of menin during embryonic stages rather than in adult stages.
Indeed, in adult mouse pancreatic islets, we did not observe significant expression of Hox genes or significant trimethylation of H3K4me3 at Hox gene promoters but did observe high levels of H3K27 methylation at Hox gene promoters (Supplementary Fig. S3 ). Thus we believe that the differences between the current and previous studies are likely to represent the effect of Men1 under different biological circumstances, although we can not exclude the possibility that some of these differences represent the effects of variation in experimental conditions. Further independent studies in consistent cell types and tissues will be required to clarify this issue in the long term.
Anti-correlation between H3K4me3 and H3K27me3 signals.
We observed that H3K27me3 signals were enriched in regions showing decreased 
likely reflects an indirect effect of Men1 loss since menin has not been known to associate with any histone K27 demethylase. However, since decreased gene expression is accompanied by decreased H3K4me3 at menin target gene promoters ( Fig. 2A) , it is conceivable that these epigenetic marks may coexist within a given cell.
Genes regulating cell fate decisions during embryonic development are often characterized by dual H3K4me3 and H3K27me3 marks (38) , a bivalent mark indicating a "poised" state which can either be activated or repressed during lineage specification.
The MLL4 methyltransferase that interacts with menin (16, 17) has been reported to regulate bivalent promoters in mouse embryonic stem cells (32) . During pancreatic islet cell differentiation some bivalent marks may keep genes silent and poised, capable of switching to either an activated or repressed state in response to the appropriate signal; genes associated with H3K4me3 alone, however, are inactivated by additional trimethylation of H3K27 (38) (Fig. 6 ). To our knowledge this is the first study providing evidence that a significant number of menin-dependent mouse genes are subject to bivalent histone modification and regulation under physiological conditions.
Igf2bp2 functions during cell differentiation and tumorigenesis.
We have identified Igf2bp2 as a menin gene target that shows an increase in H3K4me3 levels and reduction in H3K27me3, upon Men1 loss. We also observe that this inverse correlation is enhanced with increasing age and is most dramatic in Men1- Interestingly, menin has previously been shown to bind the promoter of the Igfbp2 (insulin-like growth factor binding protein 2) and to repress Igfbp2 expression in MEFs (mouse embryonic fibroblasts) (41, 42) , in addition to the effect on Igf2bp2 that we report here. We do not see significant changes for either H3K4me3 or H3K27me3 levels at the Igfbp2 locus in pancreatic islets harvested from mice at age of 2 months, suggesting that the mechanism for Igfbp2 expression by menin is different from that for Igf2bp2 expression.
In contrast, Igf2bp2 expression is dynamically regulated by epigenetic changes driven by menin-HMT complexes, and also modulated by the Rbp2 histone demethylase.
We observed that Igf2bp2 expression is decreased during the hyperplasia stage in Men1- In conclusion, we have identified several genes, notably Igf2bp2, as being regulated by menin-mediated H3K4me3 and observe epigenetic changes in these targets over time, strongly suggesting a role for these genes in pancreatic islet tumorigenesis induced upon ablation of Men1. 
